• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CryoPort Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/10/25 9:00:27 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYRX alert in real time by email
    false 0001124524 0001124524 2025-06-06 2025-06-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

      

    FORM 8-K

     

    CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 6, 2025

     

    CRYOPORT, INC. 

    (Exact name of registrant as specified in its charter)

     

    Nevada   001-34632   88-0313393
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)
             

    112 Westwood Place, Suite 350

     Brentwood, TN 37027

    (Address of principal executive offices, including zip code)
             
    Registrant’s telephone number, including area code: (949) 470-2300
     
    Not Applicable
    (Former name or former address, if changed since last report)

      

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
         
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
         
    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
         
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
         

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which
    registered
    Common Stock, $0.001 par value   CYRX   The NASDAQ Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

      

     

     

     

    Item 5.07Submission of Matters to a Vote of Security Holders.

     

    On June 6, 2025, Cryoport, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The final voting results for the proposals submitted to a vote of stockholders at the Annual Meeting, each of which is described in detail in the Company’s proxy statement filed with the U.S. Securities and Exchange Commission on April 25, 2025 (“Proxy Statement”), are set forth below.

     

    Proposal No. 1: Election of Directors. The individuals listed below were elected to serve as directors of the Company until the Company’s 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified or their earlier death, resignation, or removal:

     

    Director Nominee

    Votes For

    Votes Withheld

    Broker Non-Votes

    Linda Baddour 35,239,403 4,653,061 3,844,856
    Daniel M. Hancock 39,535,584 356,880 3,844,856
    Robert Hariri, M.D., Ph.D. 38,422,159 1,470,305 3,844,856
    Ram M. Jagannath 39,306,265 586,199 3,844,856
    Ramkumar Mandalam, Ph.D. 38,370,448 1,522,016 3,844,856
    Jerrell W. Shelton 39,476,173 416,291 3,844,856

     

    Proposal No. 2: Ratification of the appointment of Deloitte and Touche LLP as the independent registered public accounting firm of the Company and its subsidiaries for the year ending December 31, 2025. This proposal was approved as set forth below:

     

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    36,599,870 14,542 123,890 —

     

     

    Proposal No. 3: Advisory vote to approve the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. This proposal was approved as set forth below:

     

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    31,308,283 1,549,637 35,526 3,844,856

     

     

    Proposal No. 4: Advisory vote to approve the preferred frequency of future advisory votes on the compensation of the named executive officers. This proposal was approved as set forth below:

     

    1 Year

    2 Years

    3 Years

    Abstentions

    Broker Non-Votes

    31,819,718 311,644 733,429 28,655 3,844,856

     

     

    After considering the results of the vote of the stockholders on Proposal No. 4 and consistent with the recommendation of the Company’s Board of Directors, the Company will include a non-binding stockholder advisory vote to approve the compensation of its named executive officers in its proxy materials every year until the next required vote on the frequency of stockholder votes on named executive officer compensation.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: June 10, 2025 Cryoport, Inc.
       
      /s/ Robert Stefanovich
      Robert Stefanovich
      Chief Financial Officer

     

     

     

    Get the next $CYRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYRX

    DatePrice TargetRatingAnalyst
    3/24/2025$10.00Neutral → Buy
    UBS
    12/19/2024$11.00Buy
    Guggenheim
    12/19/2024$11.00Buy
    Canaccord Genuity
    8/7/2024$20.00 → $8.00Buy → Hold
    Jefferies
    7/31/2024$19.00 → $15.00Neutral → Buy
    B. Riley Securities
    5/3/2024$22.00 → $19.00Buy → Neutral
    B. Riley Securities
    4/4/2024$17.00 → $21.00Buy
    Jefferies
    3/13/2024$19.00 → $18.00Buy
    Needham
    More analyst ratings

    $CYRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cryoport Completes CRYOPDP Divestiture and Commences Strategic Partnership with DHL Group

      NASHVILLE, Tenn., June 12, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leader in temperature-controlled supply chain solutions for the Life Sciences, with a focus on regenerative medicine, today announced the completion of the previously disclosed divestiture of its specialty courier business, CRYOPDP, to DHL Group ("DHL"), one of the world's leading logistics providers, in a transaction that includes cash payments of approximately $200 million to Cryoport. Concurrently, Cryoport and DHL have established a strategic partnership aimed at e

      6/12/25 8:00:00 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cryoport Reports First Quarter 2025 Financial Results

      Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over yearQ1 2025 revenue from continuing operations of $41.0 million, up 10% year over yearSupporting 711 global clinical trials as of March 31, 2025Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025NASHVILLE, Tenn., May 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025.  Jerrell Shelton, C

      5/7/25 4:05:00 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025

      NASHVILLE, Tenn., April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global provider of supply chain solutions for the life sciences sector, today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 7, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport First Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Wednesday,

      4/24/25 8:30:00 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    SEC Filings

    See more
    • CryoPort Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Cryoport, Inc. (0001124524) (Filer)

      6/10/25 9:00:27 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by CryoPort Inc.

      SD - Cryoport, Inc. (0001124524) (Filer)

      5/30/25 4:31:07 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.

      SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)

      5/15/25 7:41:28 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CryoPort Inc.

      SC 13G - Cryoport, Inc. (0001124524) (Subject)

      11/14/24 4:02:52 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

      SC 13G/A - Cryoport, Inc. (0001124524) (Subject)

      11/14/24 1:34:13 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

      SC 13G/A - Cryoport, Inc. (0001124524) (Subject)

      11/13/24 7:16:51 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    Financials

    Live finance-specific insights

    See more
    • Cryoport Reports First Quarter 2025 Financial Results

      Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over yearQ1 2025 revenue from continuing operations of $41.0 million, up 10% year over yearSupporting 711 global clinical trials as of March 31, 2025Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025NASHVILLE, Tenn., May 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025.  Jerrell Shelton, C

      5/7/25 4:05:00 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025

      NASHVILLE, Tenn., April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global provider of supply chain solutions for the life sciences sector, today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 7, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport First Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Wednesday,

      4/24/25 8:30:00 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics"

      DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in specialty pharma logistics and supports Group's 2030 strategy to become a leader in life science and healthcare logistics.DHL and Cryoport form strategic partnership to strengthen their respective supply chain services offerings for the global life sciences and healthcare sector.BONN, Germany and NASHVILLE, Tenn., March 31, 2025 /PRNewswire/ -- DHL Group ("DHL"), the world's leading logistics provider, and Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport"), a global provider of supply chain solutions for the

      3/31/25 9:06:00 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Moffitt Cancer Center and Cryoport Announce Strategic Collaboration

      Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn., Jan. 14, 2025 /PRNewswire/ -- Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary Speros FL, a 775-acre global innovation life sciences campus, and Cryoport, Inc. (NASDAQ:CYRX), a global leader in supply chain solutions for the life sciences industry, today announced a strategic collaboration that will provide CRYOGENE's state-of-the-art biorepository services to Speros in Pasco County, Florida. Cryoport's CRYOGENE business unit is a leading biorepository for the life sciences industry that i

      1/14/25 8:30:00 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cryoport Announces Appointment of Linda Baddour to its Board of Directors

      NASHVILLE, Tenn., March 3, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has elected Linda Baddour as a member of the Board, effective March 15, 2021. Linda Baddour is a senior executive with over twenty years of experience in healthcare, life sciences and pharmaceuticals. "Our corporate governance underpins all that we do at Cryoport and we are delighted to strengthen our Board as we leverage our newly expanded global footprint and advanced temperature-controlled supply chain platform to spur our growth," said Jerrell She

      3/3/21 4:08:00 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriaCell Appoints Martin Schmieg to Board of Directors

      BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. Having previously served as a member of BriaCell’s Board of Directors from 2016 to 2019, Mr. Schmieg is a “C” level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries with 40 years of business experience. He currently serves as Co-Founder and CEO of ClearIt, L

      12/1/20 6:30:00 AM ET
      $BCTX
      $CLBS
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Managed Health Care

    $CYRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cryoport upgraded by UBS with a new price target

      UBS upgraded Cryoport from Neutral to Buy and set a new price target of $10.00

      3/24/25 8:25:01 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Cryoport with a new price target

      Guggenheim initiated coverage of Cryoport with a rating of Buy and set a new price target of $11.00

      12/19/24 7:35:39 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Cryoport with a new price target

      Canaccord Genuity initiated coverage of Cryoport with a rating of Buy and set a new price target of $11.00

      12/19/24 7:35:29 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Digital and Tech Officer Zecchini Edward J exercised 75,000 shares at a strike of $3.07 and sold $352,518 worth of shares (51,500 units at $6.84), increasing direct ownership by 35% to 90,411 units (SEC Form 4)

      4 - Cryoport, Inc. (0001124524) (Issuer)

      6/10/25 7:28:18 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hancock Daniel M was granted 23,214 shares, increasing direct ownership by 65% to 58,702 units (SEC Form 4)

      4 - Cryoport, Inc. (0001124524) (Issuer)

      6/10/25 7:27:10 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mandalam Ramkumar was granted 23,214 shares and sold $39,673 worth of shares (5,622 units at $7.06), increasing direct ownership by 30% to 77,089 units (SEC Form 4)

      4 - Cryoport, Inc. (0001124524) (Issuer)

      6/10/25 7:25:52 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care